Table 2 Literature review on the identified putative somatic missense variants in the hematological malignancy cohorts.

From: Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies

Patient ID

Cluster

Diagnosis

Variant

Cohort freq1

Public freq2

Proximal functional site

Methods

Function/mutant consequence/mutant phenotype

Reference

Organism

P6

NA

MDS

Y55H

1/756; 0.0013

0

S56F

mutagenesis

temperature-sensitive partial loss of function

Poulter [7]

human

R57

structural

ATP-contacting residue (gamma phosphate)

Lv [20]

human

R57K/A

mutagenesis

significantly reduced nitrate reductase activity in R515 (R73 in E. Coli) double mutants

Lake [40]

E. Coli (R14K/A)

P33

NA

B-ALL

D103N

1/321; 0.0031

0

S140

structural

SCCH/IAD/AAD interacting residue; substitution has minimal effect on thioester bond formation

Hann [41]

S. Pombe (Q105A)

P40

NA

T-NHL

I123T

1/148; 0.0068

0

S140

structural

SCCH/IAD/AAD interacting residue; substitution has minimal effect on thioester bond formation

Hann [41]

S. Pombe (Q105A)

P7

NA

MDS

R182H

1/756; 0.0013

gnomAD (3/165293; 1.81e-5)

A189T*

mutagenesis

slightly less efficient ubiquitination, higher apoptotic rate than wild type

Lao [42]

mouse (A189T)

P8

ATP-binding

MDS + T-NHL

A478S

1/756; 0.0013

0

A478

structural

ATP-contacting residue (alpha phosphate); consists the oxyanion hole and GxGxxG ATP binding motif

Lv [20]

human

P37

ATP-binding

B-NHL (FL)

V524D

1/541; 0.0018

0

K528N*

mutagenesis

mutant tissue apoptotic and enlarged wild type tissue (total loss of function)

Pfleger [39]

Drosophila(K663N)

K528A

structural; mutagenesis

ATP-contacting residue (beta phosphate); ATP binding attenuated and reduced Ub-adenylation

Tokgöz [43]

human

P39

ATP-binding

B-NHL (HCL)

R551C

1/541; 0.0018

0

N550*

mutagenesis

3-fold decrease in thioester bond formation

Hann [41]

S. Pombe (E511R)

R551

structural

ATP-contacting residue

Lv [20]

human

P9

Ub Interface III

CML + MPN

E597A

1/500; 0.0020

0

C588Y*

mutagenesis

mutant tissue apoptotic and enlarged wild type tissue (total loss of function)

Pfleger [39]

Drosophila (C723Y)

G599

structural

ubiquitin-contacting residue

Lv [20]

human

case

Ub Interface III

MDS

N606I

1/756; 0.0013

0

N606

structural

van der Waals contacts with Ub

Lv [20]

human

P10

Ub Interface III

MDS

S621C

1/756; 0.0013

COSMIC MDS-RS (1/9; 0.11)

S621

structural

hydrogen bond with Ub

Lv [20]

human

S621C

sequencing

somatic variant identified in a SF3B1-mut MDS patient (COSMIC-cited)

Papaemmanuil [44]

human

S621C

sequencing

somatic variant identified in a patient with vasculitis

Beck [36]

human

P36

Interdomain Interface

B-NHL (FL)

R747C

1/541; 0.0018

COSMIC colorectal carcinoma (1/619; 0.0016)

R747E*

mutagenesis

4-fold decrease in thioester bond formation

Hann [41]

S. Pomne (R707E)

R747

structural

salt bridge between E252 of the FCCH domain

Lv [20]

human

P747C

sequencing

somatic variant identified in a female patient with large intestine adenocarcinoma (COSMIC-cited)

Giannakis ()

human

P11

Interdomain Interface

MDS

P749L

1/756; 0.0013

0

P749L*

mutagenesis

enlarged mutant tissue (temperature-sensitive partial loss of function)

Pfleger [39], Lee [38]

Drosophila (P884L)

P38

Ub Interface III

B-NHL (FL)

I890T

1/541; 0.0018

0

I891

structural

van der Waals contacts with Ub

Lv [20]

human

P6

Ub Interface III

MDS

I894F

1/756; 0.0013

0

I891

structural

van der Waals contacts with Ub

Lv [20]

human

case

Ub Interface III

MDS

I894S

1/756; 0.0013

0

I891

structural

van der Waals contacts with Ub

Lv [20]

human

P12

NA

MDS

P1014L/splice

1/756; 0.0013

0

R1010

structural

E2 enzyme (Ubc4) contact site

Olsen [45]

S. Pombe (R965)

del(923-1058)

mutagenesis

IRF3 binding lost

Chen [46]

human/zebrafish

  1. [*] indicates that the site is a corresponding conserved residue in human.
  2. 1: The frequency in the respective subcohort.
  3. 2: The frequency reported in gnomAD or COSMIC databases. In case of COSMIC the cancer name is given and the frequency is in the brackets.
  4. Subject Ontology:UBA1, VEXAS, MDS, inflammation, cytopenia, leukemia, lymphoma, sex difference.